Here, (−)-epicatechin treatment reduced KRAS mutant pancreatic cancer cell viability but not that of normal cells, and it also reduced GTP-bound Ras protein levels, Akt phosphorylation, and NF-κB transcriptional activity. Here, KRAS is linked to pancreatic neoplasm.